NAYA Biosciences Inc
NASDAQ:NAYA
NAYA Biosciences Inc
Total Liabilities & Equity
NAYA Biosciences Inc
Total Liabilities & Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Liabilities & Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
NAYA Biosciences Inc
NASDAQ:NAYA
|
Total Liabilities & Equity
$17m
|
CAGR 3-Years
28%
|
CAGR 5-Years
46%
|
CAGR 10-Years
N/A
|
|
|
Becton Dickinson and Co
NYSE:BDX
|
Total Liabilities & Equity
$54.7B
|
CAGR 3-Years
1%
|
CAGR 5-Years
1%
|
CAGR 10-Years
11%
|
|
|
Boston Scientific Corp
NYSE:BSX
|
Total Liabilities & Equity
$38.1B
|
CAGR 3-Years
6%
|
CAGR 5-Years
4%
|
CAGR 10-Years
8%
|
|
|
Stryker Corp
NYSE:SYK
|
Total Liabilities & Equity
$43B
|
CAGR 3-Years
7%
|
CAGR 5-Years
7%
|
CAGR 10-Years
10%
|
|
|
Abbott Laboratories
NYSE:ABT
|
Total Liabilities & Equity
$81.4B
|
CAGR 3-Years
3%
|
CAGR 5-Years
4%
|
CAGR 10-Years
7%
|
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Total Liabilities & Equity
$18.7B
|
CAGR 3-Years
11%
|
CAGR 5-Years
14%
|
CAGR 10-Years
17%
|
|
NAYA Biosciences Inc
Glance View
INVO BioScience, Inc. is a fertility company. The company is headquartered in Sarasota, Florida and currently employs 25 full-time employees. The company went IPO on 2008-11-11. The Company’s initial pipeline includes two novel Flex-NK Bispecific Antibodies. NY-303: its GPC3-targeted FLEX-NK Bispecific Antibody for Hepatocellular Carcinoma (HCC). NY-338: its CD38-targeted FLEX-NK Bispecific Antibody for Multiple Myeloma (MM) & Autoimmune Diseases. Its lead GPC3-targeting FLEX-NK bispecific antibody is entering Phase I/II clinical trials and positioned as a monotherapy option to address the unmet needs of the of hepatocellular carcinoma (HCC) patients not responding to standard of care with checkpoint inhibitors. INVOcell is its novel, FDA-cleared and CE-marked intravaginal culture (IVC) device. The company offers a viable alternative to vitro fertilization (IVF) that uses the female body for fertilization and incubation, keeping women at the center of the reproductive process.
See Also
What is NAYA Biosciences Inc's Total Liabilities & Equity?
Total Liabilities & Equity
17m
USD
Based on the financial report for Sep 30, 2024, NAYA Biosciences Inc's Total Liabilities & Equity amounts to 17m USD.
What is NAYA Biosciences Inc's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 5Y
46%
Over the last year, the Total Liabilities & Equity growth was -13%. The average annual Total Liabilities & Equity growth rates for NAYA Biosciences Inc have been 28% over the past three years , 46% over the past five years .
You don't have any saved screeners yet